SCHEMBL4717102

SCHEMBL4717102

N#Cc1cc2c(ccc(=O)n2-c2ccccc2)n1Cc1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.46
MAPK9 P45984 1/20 0.46
MAPT P10636 3/20 0.45
ALDH1A1 P00352 4/20 0.43
RGS4 P49798 1/20 0.43
RGS8 P57771 1/20 0.43
LMNA P02545 2/20 0.42
CCR2 P41597 2/20 0.42
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PGR P06401 2/20 0.41
ATM Q13315 1/20 0.40
USP2 O75604 1/20 0.40
HPGD P15428 2/20 0.40
PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119050 0.81 CCR2 (0.62) MAPK8MAPK9MAPTCCR2ERCC5
SCHEMBL4715213 0.79 CCR2 (0.51) MAPK8MAPK9MAPTALDH1A1RGS4
SCHEMBL4711188 0.78 BRD4 (0.53) MAPK8MAPK9MAPTALDH1A1RGS4
SCHEMBL4717022 0.78 CCR2 (0.49) MAPK8MAPK9MAPTALDH1A1RGS4
SCHEMBL4716161 0.78 MAPT (0.42) MAPK8MAPK9MAPTALDH1A1RGS4
SCHEMBL4715185 0.77 BRD4 (0.48) MAPK8MAPK9MAPTALDH1A1LMNA
SCHEMBL4716315 0.75 ALDH1A1 (0.47) MAPK8MAPK9MAPTALDH1A1RGS4
SCHEMBL4714899 0.75 ALDH1A1 (0.49) MAPK8MAPK9MAPTALDH1A1LMNA
SCHEMBL4712174 0.75 MAPT (0.51) MAPTALDH1A1LMNACCR2KMT2A
SCHEMBL4712460 0.75 PTGS2 (0.51) MAPTALDH1A1LMNACCR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 MAPK8 42/4885MAPK9 53/4885MAPT 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.